% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • boxcarlong boxcarlong Apr 9, 2013 12:44 PM Flag

    -011 P3 trial primary end point is increase in the overall survival rate

    So boys & girls go back and look at P2 results .... increase in survival was 6.9 Months

    Yes the shorts point to PSA rates So What. .... thats not the primary end point.

    The Drug has both an SPA and Fast track FDA Designation. Both very important to a speedy Filing

    so as long as the P3 trial meets SPA trial end point its a done deal.


0.3705+0.0004(+0.11%)Oct 25 4:00 PMEDT